6/28/23, 12:03 AM CAPRIE Pathway Feedback Search Clinical Topics Home Studies CAPRIE CAPRIE Disease Disease Coronary artery disease Transient ischemic attack Trial question Is clopidogrel superior to aspirin in patients with atherosclerotic vascular disease? Study design Multi-center Double blinded RCT Population Characteristics of study participants 28.0% female N = 19185 72.0% male 19185 patients (5372 female, 13813 male) Inclusion criteria: patients with atherosclerotic vascular disease Key exclusion criteria: age < 21 years, women of childbearing age not using reliable contraception, uncontrolled hypertension, scheduled for major surgery, or contraindications to study drugs Interventions N=9599 clopidogrel (75 mg daily) N=9586 aspirin (325 mg daily) Primary outcome Ischemic stroke, myocardial infarction, or vascular death 5.8 % 5.83 5.32 4.4 % https://web.pathway.md/studies/recCvxEEUZwV4H1KV 1/2 6/28/23, 12:03 AM CAPRIE Pathway 2.9 % Significant decrease 1.5 % NNT = 196 0.0 % Clopidogrel Aspirin Significant decrease in ischemic stroke, myocardial infarction, or vascular death (5.32% vs. 5.83%; RR 0.91, 95% CI 0.84 to 0.97) Secondary outcomes No significant difference in ischemic stroke, MI, amputation, or vascular death (5.56% vs. 6.01%; RR 0.92, 95% CI 0.85 to 1.08) Safety outcomes No significant difference in adverse events. Conclusion In patients with atherosclerotic vascular disease, clopidogrel was superior to aspirin with respect to ischemic stroke, myocardial infarction, or vascular death. Reference CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet. 1996 Nov 16;348(9038):1329-39. Open reference URL https://web.pathway.md/studies/recCvxEEUZwV4H1KV 2/2